1. Introduction {#s0005}
===============

Episodic memory impairments are common in Parkinson\'s disease (PD). Over 20% of newly diagnosed patients express a memory complaint ([@bb0030]) and two large cohorts of newly diagnosed PD patients reported frequent memory impairments on baseline testing ([@bb0250]; [@bb0260]). Episodic memory impairments are reported almost as frequently as executive dysfunction ([@bb0005]), however patients who experience episodic memory impairments are at higher risk of developing dementia than those who experience executive dysfunction alone ([@bb0100]; [@bb0225]). There are no effective treatments to prevent or delay the memory impairments leading to dementia, in part because the neuroanatomical underpinnings of PD-related episodic memory impairments are not well understood.

Autopsy studies have shown that alpha-synuclein pathology in the hippocampus is common in PD patients, which could be related to memory impairments ([@bb0105]; [@bb0010]). According to the Braak staging system in PD, Lewy neurites and Lewy-bodies develop in the hippocampus at stage 4, before Lewy-bodies develop elsewhere in the neocortex (stages 5--6) ([@bb0025]; [@bb0020]). One clinicopathological study showed that almost 90% of patients identified as Braak stage 4 at autopsy (hippocampal Lewy-bodies without other neocortical Lewy-body pathology) were cognitively impaired prior to death. While these autopsy studies provide invaluable insights into the pathology associated with PD dementia (PDD), they are limited to the end of that pathological process when the brain has been ravaged by disease; and therefore, these studies are insensitive to the earliest brain changes more likely to be associated with mild memory impairments.

Pre-mortem, structural MRI can overcome this challenge. To date, most MRI studies agree that PD patients with dementia have smaller hippocampi than healthy adults but larger hippocampi than Alzheimer\'s disease (AD) patients ([@bb0045]; [@bb0035]; [@bb0160]; [@bb0205]); however, studies in early PD patients have been mixed ([@bb0045]; [@bb0035]; [@bb0160]; [@bb0245]; [@bb0210]). These conflicting results could have arisen from evaluating the hippocampus as a single structure. This is important to consider because Lewy-body pathology is not found uniformly throughout the hippocampus. For instance, Lewy-body pathology is most prominent in the CA2 subfields ([@bb0085]; [@bb0090]) but is also found throughout CA1([@bb0065]). By contrast, the dentate gyrus (DG/CA3) is relatively free of Lewy-body pathology. Further, while CA2 and CA1 have a predilection for Lewy-body pathology, a recent autopsy study found that the degree of Lewy-body pathology in CA1, but not CA2, predicted pre-mortem episodic memory impairment in patients with LewyBody Dementia ([@bb0010]). The clinical impact of this regional distribution of pathology in the hippocampal subfields, and the CA1 subfield in particular, has not been well studied in earlier PD patients, prior to the onset of dementia.

Here, we sought to determine whether episodic memory impairments in PD can be predicted by specific hippocampal subfields (as an in vivo proxy for regional Lewy-body pathology). To achieve this goal, we leveraged ultra-high field 7-Tesla (7T) MRI to generate images with high enough spatial resolution to visually identify and manually segment and quantify the thickness of sublayers of CA1, along with the area of DG/CA3 and the whole hippocampus ([@bb0150]; [@bb0145]; [@bb0140]). We then determined whether hippocampal subfield microstructural size was related to episodic memory in a cohort of mostly non-demented PD participants.

2. Methods {#s0010}
==========

2.1. Standard protocol approvals, registrations, and patient consents {#s0015}
---------------------------------------------------------------------

All study procedures were approved by the Stanford Institutional Review Board. Written informed consent was obtained from all participants in this study.

2.2. Participants {#s0020}
-----------------

We recruited 38 PD and 10 healthy controls (HC) participants from the Stanford Movement Disorders Clinic and the surrounding community. Inclusion criteria were (1) age between 50 and 79 years, (2) English fluency, (3) right-handedness, (4) no MRI structural abnormalities (including stroke), (5) no past or current history of alcohol abuse, substance abuse, head injury with loss of consciousness ≥15 min, epilepsy, hydrocephalus, or major psychiatric disorder, and 6) no known or potential contraindications to high magnetic field. For PD, additional exclusion criteria were (1) deep brain stimulation and (2) features suggestive of an atypical parkinsonian syndrome (early repeated falls, early symptomatic orthostatic hypotension, or early visual hallucinations).

2.3. Clinical assessments {#s0025}
-------------------------

A board-certified neurologist with specialty training in movement disorders completed a history, general physical examination and neurological examination. Participants with PD performed the Movement Disorders Society Unified Parkinson\'s Disease Rating Scale, part III motor exam (MDS-UPDRS-III) ([@bb0115]) in the clinically-defined off dopaminergic state, according to published protocols ([@bb0215]), and were diagnosed with probable PD using the UK Parkinson\'s Disease Society Brain Bank clinical diagnostic criteria ([@bb0170]). A trained psychometrician administered comprehensive neuropsychological testing to all participants. The neurologist and psychometrician where blinded to the MRI segmentation data. As recommended by the Movement Disorder Society commissioned task force ([@bb0175]), the neuropsychological battery included at least two tests in each of five cognitive domains (episodic memory, attention/working memory, executive, visuospatial, and language) and an additional test of general cognition (Montreal Cognitive Assessment) ([@bb0190]). Based on our central hypothesis that hippocampal subfield microstructural size is related to memory performance in PD and based on our prior publications ([@bb0140]), we focused the analysis on episodic memory cognitive measures taken from the California Verbal Learning Test-II (CVLT-II) ([@bb0080]). Specifically, we studied (1) immediate memory (CVLT-II short delay, free recall), (2) delayed memory (CVLT-II long delay, free recall), (3) delayed cued memory (CVLT-II long delay, cued recall), and (4) learning (CVLT-II trials 1--5 summation). We included delayed cued memory since several studies suggest that in PD patients poor cued recall is more likely due to a memory impairment per se, whereas poor free recall could be due to either memory or executive impairments ([@bb0205]; [@bb0095]; [@bb0070]).

2.4. Image acquisition {#s0030}
----------------------

All 48 enrolled participants were scanned with a 7T GE Healthcare Discovery MR950 MRI whole-body scanner (GE Healthcare, Waukesha, WI) using a 32-channel radiofrequency receive head coil contained within a quadrature transmit coil (Nova Medical, Inc., Wilmington, MA). Sixteen oblique coronal images oriented perpendicular to the longitudinal axis of the hippocampus were acquired with a T2-weighted fast spin echo sequence: echo time 47 milliseconds; repetition time 5--8 s (cardiac gated); acquired voxel size was 0.22 × 0.22 × 1.5 mm^3^ with a slice gap of 0.5 mm, interpolated by zero filling to 0.166 × 0.166 × 1.5 mm^3^.

To minimize head motion, we stabilized each participant\'s head by positioning inflatable and/or foam cushions between the surface of the head and the inner surface of the receive coil. For subjects exhibiting tremor, we placed soft, weighted bags atop the limbs to reduce the potential transmission of tremor motion to the head. We placed a plethysmograph on one index finger to monitor peripheral pulse. PD participants were scanned in the typical on-medication state ([@bb0200]).

2.5. 7T image analysis {#s0035}
----------------------

We traced regions-of-interest (ROIs) using FSL-view, a component of the FSL 5.0.10 software package (<http://www.fmrib.ox.ac.uk/fsl/>), and OsiriX 8.5 software package (<http://www.osirix-viewer.com/>). We used previously validated semi-automated methods for subfield identification and derivation of subfield metrics ([@bb0145]; [@bb0140]).

We focused our analysis on the thickness of the CA1 stratum pyramidale (CA1-SP) and stratum radiatum lacunosum moleculare (CA1-SRLM) layers, and the cross-sectional area of the DG/CA3 and the whole hippocampus ([Fig. 1](#f0005){ref-type="fig"}). We choose CA1-SP as the primary variable of interest because Lewy-bodies are found in the cell bodies of the CA1 subfield post-mortem ([@bb0025]), which has been correlated with pre-mortem memory performance ([@bb0010]). We included DG/CA3 as a 'control' region because it is relatively spared of Lewy-bodies post-mortem. We included the whole hippocampus for comparison to prior publications. While Lewy-bodies are also prominent in the CA2 subfield at autopsy, this region is not visually discernable even with high-resolution imaging and prior attempts to manually segment CA2 have shown poor inter-study reliability ([@bb0265]), therefore we did not include CA2 measures. For all analyses, we separately estimated then averaged the right and left hemispheres. We used raw metrics, rather than adjust for head size, based on our previous data that strongly suggests that these raw measures are likely to reflect the presence of pathology and do not vary with intracranial volume ([@bb0135]).Fig. 1Hippocampal subfields illustrations on images obtained at 7T MRI. A) Oblique coronal view of a 7T T2-weighted MRI scan. B) Magnified area of the hippocampus where subfields are readily visualized and thus able to be manually traced. C) Superimposed manual tracing of the CA1 (red) and DG/CA3 (turquoise). Abbreviations: R: right, L: left.Fig. 1

To estimate the thickness of CA1-SP, we manually traced curvilinear ROIs on the hyperintense region of the CA1-SP in each slice within the delimiting boundaries of the hippocampal body ([Fig. 2](#f0010){ref-type="fig"}). We then estimated the thickness of the CA1-SP using an in-house semi-automated method measuring the widths of derived orthogonal vectors from a computed spline. Specifically, the in-house semi-automated algorithm derives orthogonal vectors along a spline generated from the user-specified line of hyperintensity. We used a distance-from-spline function with each signal intensity-distance averaged with its corresponding reverse function to obtain a true midpoint of the structure of interest. We estimated the thickness of the CA1-SP as the distance between the peak and the trough of the derivative of the signal intensity-distance function ([@bb0140]).Fig. 2Estimation of CA1-SP thickness using in-house semi-automated algorithm. *Top:* Magnification of the CA1-SP region and the re-centered orthogonal vectors to the spline of the traced ROI used in the CA1-SP thickness estimation. Yellow squares show traced ROIs, red lines show orthogonal planes to the spline, and white arrows show the re-centered orthogonal vectors where thickness is estimated. *Bottom:* CA1-thickness is estimated as the average distance between the peak and the trough of the 1st derivative of the intensity plot. Methods described in detail by Kerchner et al. Neuroimage [@bb0140].Fig. 2

Similarly, we estimated the thickness of the CA1-SRLM using the curvilinear ROI tracings, but on the hypointense band between the more intense DG and CA1-SP cell layers ([@bb0140]). This was followed by an akin implementation of the semi-automated algorithm and estimation of thickness as the distance between the peak and trough of the derivative of the signal intensity-distance function.

As part of our quality checks, we did not draw an ROI when there was (1) insufficient image contrast/clarity for identification of the superior and inferior boundaries of the CA1, (2) excessive blurring of these boundaries due to motion, (3) inadequate coverage of the hippocampus, either from non-optimal slice prescription or signal drop-out, or (4) distorted CA1 uniformity due to the presence of a hippocampal sulcal remnant cyst.

To estimate cross-sectional area of the DG/CA3 and whole hippocampus, we manually traced ROIs on each slice within the delimiting boundaries of the hippocampal body.([@bb0140]) We combined DG and CA3 areas because no visible boundary can be confidently identified, even on our high-resolution images. CA4 was considered part of CA3.

All manual ROI tracings required a minimum of 4 measurable slices to be included for analysis. We excluded 11 participants (9 PD and 2 HC) that did not meet these criteria, resulting in a final cohort of 29 PD and 8 HC included in the 7T analysis ([Table 1](#t0005){ref-type="table"}).Table 1Demographics and clinical characteristics of participants included in 7T MRI analysis.Table 1HCPD*p*Total829Age, y67.9 ± 6.8 (57--76)65.5 ± 7.8 (52--79).41Female, *n* (%)^†^5 (62.5%)15 (51.7%).23Education, y17.3 ± 2.1 (14--20)16.7 ± 2.7 (12−20).58Disease duration, yn/a4.5 ± 3.0 (1--15) *n* (%) PD 0--5 y19 (65.5%) *n* (%) PD 6--10 y9 (31.0%) *n* (%) PD 11--16 y1 (3.5%)MDS-UPDRS-III (Off)n/a33.7 ± 13.6 (6--62)Cognitive diagnosis *n* (%) NC8 (100%)18 (62.1%) *n* (%) PD-MCI8 (27.6%) *n* (%) PDD3 (10.3%)MoCA^††^27.6 ± 2.2 (24--29)25.5 ± 3.9 (14--29).14CVLT^††^ Immediate memory10.9 ± 2.4 (7--15)9.1 ± 3.8 (0--15).23 Delayed memory11.8 ± 2.3 (9--16)9.4 ± 4.6 (0--16).22 Delayed cued memory12.4 ± 1.5 (10--16)11.0 ± 3.7 (2--16).36 Learning51.6 ± 4.7 (45--59)44.8 ± 12.6 (14--67).15[^2][^3][^4]

2.6. Validation of 7T semi-automated CA1-SP and CA1-SRLM thickness measurement {#s0040}
------------------------------------------------------------------------------

Our semi-automated hippocampal segmentation technique has been validated in healthy older adults ([@bb0050]), and in amnestic mild cognitive impairment and AD ([@bb0150]; [@bb0145]; [@bb0140]). Because this is the first application of this technique in PD, we performed a validation step with two independent and blinded raters, who performed the manual tracing and semi-automated CA1-SP and CA1-SRLM thickness estimations. Data from rater 1 were used for statistical analyses and data from raters 1 and 2 were used to calculate interrater reliability. We applied a two-way-mixed level ANOVA and computed the absolute intraclass correlation coefficient (ICC) ([@bb0235]). We found an absolute ICC value of 0.86 for CA1-SP mean thickness values (95% CI: 0.70--0.93) and 0.77 for CA1-SRLM mean thickness values (95% CI: 0.54--0.89).

2.7. CSF analysis {#s0045}
-----------------

Comorbid Alzheimer\'s disease (AD) pathology in our PD cohort could confound the interpretation of our hippocampal measurements. In prior work, we demonstrated CA1-SP and CA1-SRLM thinning in amnestic mild cognitive impairment and in patients with mild AD relative to healthy controls, and this thinning was highly correlated to memory performance. Therefore, in a subset of participants, we obtained CSF by lumbar puncture between the L3/L4 or L4/L5 intervertebral space and collected in 20-mL polypropylene tubes. We centrifuged CSF samples for 10 min at 1800 × *g* at 4 °C within 2 h of collection and divided into aliquots in polypropylene tubes of 0.5 or 1 mL at −80 °C until analysis. We measured Aβ1--42 and p-tau using commercially available ELISA kit according to the manufacturer\'s protocol. Because reference values for these proteins can vary, we determined the cutoff for low Aβ1--42 and elevated p-tau using an independent cohort of 21 healthy controls and 14 clinical AD participants, who had CSF processed at the same time. We used an ROC analysis to determine that a cutoff of Aβ1--42 ≤ 660 and p-tau ≥60 gave 100% sensitivity with 92% specificity (AUC = 0.98) differentiating AD from the healthy controls. We then dichotomize PD participants who have CSF in this range (Aβ1--42 ≤ 660 and p-tau ≥60) as 'possible dual PD/AD'.

2.8. Statistical analysis {#s0050}
-------------------------

We used the Statistical Package for the Social Sciences (IBM SPSS Statistics, version 24; IBM Corp, <https://www.ibm.com/>) for all statistical analyses and used two-tailed *p* values. For between-group analysis, we calculated two-sample *t*-tests for continuous variables with equal variance, Mann--Whitney U for continuous variables with unequal variance, and chi-square for dichotomous variables. For univariate correlational analyses between continuous variables, we calculated Pearson coefficients. To assess whether episodic memory in PD is best predicted by hippocampal subfield metrics or clinical measures, we performed three linear regression models in the whole PD cohort, with episodic memory cognitive measures as the dependent variable and hippocampal subfield metrics, age, disease duration, education, gender, and CSF (dichotomous for possible dual PD/AD pathology) as independent variables. In model 1, we performed a linear regression with only the primary variable of interest (CA1-SP) as the independent variable (unadjusted model). In model 2, we included the minimal adjustment by adding age into the model (age-adjusted model). We chose age because it is the strongest predictor of memory in healthy aging and in PD ([@bb0060]; [@bb0220]). In model 3, we performed a fully-adjusted model with all clinical measures associated with memory impairment in PD (age, disease duration, education, gender, and CSF) as independent variables (fully-adjusted model). We repeated these regression analyses for CA1-SRLM, DG/CA3, and whole hippocampus.

3. Results {#s0055}
==========

3.1. Behavioral results {#s0060}
-----------------------

See [Table 1](#t0005){ref-type="table"} for complete demographic characteristics. The PD and HC participants did not differ in age, gender, or education. On formal neuropsychological testing, all HC participants were within 1.5 standard deviations of age- and education-matched normative values. For the PD participants enrolled, 18 had cognition in the normal range (PD-NC), 8 had mild cognitive impairment (PD-MCI), and 3 had dementia (PDD), according to published criteria ([@bb0100]; [@bb0175]). For this analysis we used memory as a continuous variable rather than subdividing PD by cognitive group because (1) less than half of the cohort were cognitively impaired, with very few diagnosed as PDD and (2) the designation of PD-MCI is not based on any one domain and requires two abnormal tests, therefore PD-MCI can represent highly heterogeneous patients. As a result, some patients can be designated PD-MCI without any deficits in episodic memory and others can be designated PD-NC with an episodic memory deficit that is found on only one test.

CSF protein analysis was available for 26 participants (18 PD and 8 HC) ([Table 2](#t0010){ref-type="table"}). Using our criteria above, 5 PD participants were categorized as possible dual PD/AD. Compared to the remaining 24 PD participants (13 with negative AD CSF biomarkers and 11 with unknown AD CSF biomarkers), the 5 participants with possible dual PD/AD pathology were older (63.6 ± 6.7 and 74.2 ± 5.7, *p* = .003), had more severe MDS-UPDRS-III off (30.2 ± 11.1 and 48.8 ± 12.3, *p* = .002), and lower MoCA (26.7 ± 2.3 and 21.0 ± 5.4, *p* = .001).Table 2Participants with CSF.Table 2HCPD-NCPD-MCIPDDTotal PDTotal participants8188329Participants with CSF8105318 Positive AD CSF biomarkers01225 Negative AD CSF biomarkers893113Unknown AD CSF biomarkers083011[^5][^6]

3.2. 7T hippocampal correlations and linear regression {#s0065}
------------------------------------------------------

As an initial exploratory analysis that did not control for other factors, we used univariate analysis by Pearson\'s correlation to test the relationship between memory performance in PD and our independent variables, including hippocampal metrics and clinical variables that have previously been associated with poor memory performance in PD patients ([@bb0060]) ([Table 3](#t0015){ref-type="table"}). We found that poorer immediate memory (*r* = 0.557, *p* = .005), delayed memory (*r* = 0.554, *p* = .005), delayed cued memory (*r* = 0.626, *p* = .001), and learning (*r* = 0.618, *p* = .001) were associated with thinner CA1-SP but not CA1-SRML, DG/CA3 area, or total hippocampus ([Fig. 3](#f0015){ref-type="fig"}; [Table 3](#t0015){ref-type="table"}). We then tested to see if correlations differed across regions. For each of the three measures of memory performance, the correlation with CA1-SP was significantly greater than the correlation with DG/CA3 and with CA1-SRLM, whereas the correlation with CA1-SP versus the correlation with total hippocampus did not statistically differ ([Table 3](#t0015){ref-type="table"}). Regarding clinical measures associated with memory, we found poorer immediate memory (*r* = −0.401, *p* = .031), delayed memory (*r* = −0.410, *p* = .027), delayed cued memory (*r* = −0.385, *p* = .039), and learning (*r* = −0.430, *p* = .020) were also associated with older age, but not with disease duration or education. Importantly, given the modest sample size, we note that some caution is warranted in interpreting the effect sizes of these significant relationships.Table 3Brain regions showing significant functional connectivity changes (post-treatment minus pre-treatment) with right hippocampus and bilateral ACC as seeds.Table 3Immediate MemoryDelayed MemoryDelayed Cued Memoryr (p)r (p)r (p)Clinical Characteristics Age**-0.40 (0.031)\*-0.41 (0.027)\*-0.39 (0.039)\*** Duration-0.29 (0.123)-0.27 (0.152)-0.27 (0.165) Education-0.08 (0.698)-0.06 (0.767)-0.11 (0.556)  7T MRI Metrics CA1-SP**0.56 (0.005)\*0.55 (0.005)\*0.63 (0.001)\*** CA1-SRLM0.06 (0.779)0.01 (0.966)-0.084 (0.683) DG0.02 (0.913)0.02 (0.905)0.03 (0.866) Total Hippocampus0.27 (0.155)0.35 (0.066)0.29 (0.125)  z (p)z (p)z (p)Between correlation differences CA1-SP vs CA1-SRLM1.9 (0.06)**2.02 (0.04)\*2.71 (0.007)\*** CA1-SP vs DG**2.07 (0.04)\*2.05 (0.04)\*2.39 (0.02)\*** CA1-SP vs Total Hippocampus1.19 (0.23)0.90 (0.37)1.48 (0.14)[^7][^8]Fig. 3Hippocampal and clinical correlations with episodic memory in Parkinson\'s disease. Scatter plots of delayed cued memory, delayed memory, immediate memory, and learning versus CA1 stratum pyramidale layer (CA1-SP) width in mm (A, C, E and G respectively) and age in years (B, D, F and H respectively). Regression lines only include the three PD groups (circles: PD with normal cognition in blue, PD with mild cognitive impairment in yellow, and PD with dementia in green). Healthy Control data (×) are included for reference only.Fig. 3

We then performed linear regression analysis to determine the effect of the independent variables on memory performance in the PD participants. In all age-adjusted models, CA1-SP remained a significant predictor of immediate (*p* = .012), delayed (*p* = .011), delayed cued (*p* = .004) memory, and learning (*p* = .003) (Supplemental Table 1, Supplemental Table 2, [Table 4](#t0020){ref-type="table"}, and Supplemental Table 3, respectively). In the fully-adjusted model, CA1-SP remained a significant predictor of delayed cued memory (*p* = .010) and learning (*p* = .026), but also trended toward significance for immediate (*p* = .075) and delayed (*p* = .058) memory. When comparing all models, the fully-adjusted model most strongly predicted delayed cued memory in PD; this model explained 50.6% of the variance (*R*^*2*^) and only CA1-SP remained a significant predictor (*p* \< .05, [Table 4](#t0020){ref-type="table"}).Table 4Predictors of delayed cued memory in Parkinson\'s disease.Table 4CovariatesModel 1 unadjustedModel 2 age-adjustedModel 3 fully-adjustedCA1-SP**14.00 (3.72)**^**⁎⁎**^**12.80 (3.99)**^**⁎**^**13.44 (4.65)**^**⁎**^Age−0.08 (0.09)−0.10 (0.12)Duration−0.36 (0.30)Education−0.48 (0.30)Gender1.71 (1.58)Possible dual PD/AD1.54 (2.44)***R***^**2**^ ***=* 0.391*R***^**2**^ ***=* 0.412*R***^**2**^ ***=* 0.506*p* =** **.001*p* =** **.004*p* =** **.039**[^9][^10][^11][^12]

When comparing the 29 PD and 8 HC participants, there were no between-group differences in CA1-SP (*p* = .26), CA1-SRLM (*p* = .56), DG/CA3 (*p* = .77) or total hippocampal (*p* = .61) metrics.

4. Discussion {#s0070}
=============

In this study we found that the best predictor of episodic memory performance in mostly non-demented PD patients was thinning of the CA1-SP layer of the hippocampus, as measured using 7T MRI. In our regression analyses, CA1-SP remained the only significant predictor of memory and learning after adjusting for other clinical measures associated with poor memory in PD. Together, these data are the first in living patients to clearly demonstrate that the CA1-SP hippocampal subfield is linked to memory performance in patients with PD.

4.1. Episodic memory in PD {#s0075}
--------------------------

The frequency and severity of episodic memory impairments in patients with PD has a significant impact on quality of life. Even at the stage of initial motor diagnosis, episodic memory is as commonly impaired as executive function ([@bb0250]; [@bb0260]). Additionally, the proportion of patients with episodic memory impairment increases as the disease progresses and is a major component of dementia in PD patients ([@bb0100]), markedly increasing patient disability, loss of employment, institutionalization, and mortality ([@bb0120]; [@bb0125]).

Despite this, the neural underpinning of episodic memory impairments in PD remains unclear ([@bb0075]); thus, there are almost no symptom-specific therapies available for patients, and no therapies to halt or slow the progression of impairment leading to dementia. Episodic memory impairments in PD were traditionally considered 'subcortical' and secondary to dopamine deficiency and subsequent fronto-striatal dysfunction, with inefficient use of strategies during encoding or recall ([@bb0180]). However, more recent studies have challenged the notion that memory impairment in PD is purely subcortical and only secondary to underlying executive dysfunction, and instead hypothesized additional hippocampal mechanisms ([@bb0225]). For instance, PD patients show loss of dopaminergic intervention to the hippocampus from the ventral tegmental area ([@bb0110]). This ventral tegmental area-hippocampal loop disruption has particular implications for motivationally significant memories ([@bb0165]; [@bb0230]) and dopaminergic input has been shown to influence hippocampal long-term potentiation ([@bb0055]). Another potential mechanism underlying PD episodic memory impairment is direct hippocampal pathology ([@bb0075]), which is supported by our data. Further, our data argue that, within the hippocampus, abnormalities in the CA1 region could specifically contribute to mild memory impairments in PD patients prior to the onset of dementia.

4.2. The hippocampus and CA1 in PD {#s0080}
----------------------------------

Prior studies assessing the relationship between total hippocampal volume and PD episodic memory performance have been conflicting, likely due to different methods used to acquire images and measures of the hippocampus. In general, early studies agreed that PD patients with dementia have smaller hippocampal volumes than healthy age-matched control subjects but larger hippocampal volumes than patients with clinical AD ([@bb0045]; [@bb0035]; [@bb0160]). Visual medial temporal lobe grading on a standardized 5-point atrophy severity scale showed atrophy was less severe in non-demented PD compared to AD ([@bb0240]) and that medial temporal lobe volumes could readily discriminate pathologically confirmed AD compared to Lewy Body Dementia ([@bb0040]). However, this 5-point atrophy severity scale was not sensitive enough to identify any correlation between changes in medial temporal lobe volume and severity of cognitive impairment in PD patients, either with or without dementia. Other studies that used more sophisticated hippocampal tracing techniques did find a correlation between decreases in memory and hippocampal volume ([@bb0015]; [@bb0130]), but only when including PD patients with dementia. In our study, we did not find a relationship between whole hippocampal volume/area and memory impairment in PD using 7T MRI, likely because our subjects were younger, mostly non-demented, and had a far shorter average disease duration than prior studies (duration of motor symptoms 4.5 ± 3.0 years versus 10--13 years). Thus, our results suggest that in early PD the CA1 region shows structural differences associated with memory impairments before other hippocampal structures. This is important, since biomarkers sensitive to early, mild changes are needed to identify patients at risk for developing future dementia. Further studies assessing whether hippocampal subfield size predicts worsening episodic memory with resultant PD dementia are therefore needed.

Our focus on hippocampal subfields, and CA1 in particular, is founded on previous autopsy studies that show alpha-synuclein and Lewy-body pathology preferentially affect some regions of the hippocampus more than others. While Lewy-body pathology at autopsy is most prominent in the CA2 subfields ([@bb0085]; [@bb0090]) these regions have been difficult to individually distinguish even at high resolution and have poor inter-study reliability ([@bb0265]). Therefore, we concentrated our analysis on the hippocampal subfields where segmentation techniques have been well-validated with consistent inter-rater reliability, namely CA1 and DG/CA3([@bb0150]; [@bb0145]; [@bb0140]; [@bb0135]). Of these, only CA1-SP thickness correlated with episodic memory impairment in PD, whereas CA1-SRLM thickness and DG/CA3 area did not. Further, the strength of the memory correlation with CA1-SP was greater than that with DG/CA3. This is consistent with autopsy studies that show Lewy-body pathology is found throughout the cell bodies of CA1([@bb0065]) and not in DG/CA3. This association suggests Lewy-body pathology in CA1 could be a cause of episodic memory impairments in PD. A recent neuropathological study in Lewy Body Dementia patients also supports this hypothesis, where the severity of Lewy-body pathology in CA1 (but not CA2) predicted pre-mortem episodic memory impairment ([@bb0010]). This finding may reflect a sensitive role of CA1 in episodic memory function. Additional studies in PD patients with longitudinal imaging and post-mortem analysis are needed to verify this relationship.

There are several mechanisms by which Lewy-bodies in the hippocampus might disrupt normal memory function. The current study describes structural alteration (thinning) of the CA1-SP presumably due to neuronal loss; however, the presence of alpha-synuclein may also interfere with neurochemical or synaptic signaling within this region. Churchyard and Lees suggested that Lewy neurite formation in CA2 disrupts hippocampal function by interfering with inputs to CA1. In that study, Lewy neurite density in the CA2 subfield of the hippocampus was related to the severity of dementia ([@bb0065]). A more recent study using optical imaging of in vitro mouse hippocampal neurons found that alpha-synuclein accumulation at synaptic membranes of CA1 neurons interfered with synaptic transmission at the level of vesicular recycling ([@bb0195]). Further animal studies showed accumulating alpha-synuclein severely affects hippocampal neurogenesis in a transgenic rat model of PD ([@bb0155]). As with all transgenic PD animal models, it is unclear if these findings hold true in sporadic onset disease in humans. While structural imaging cannot directly probe how these proposed mechanisms cause changes in memory performance, our findings support these transgenic animal models by showing a relationship between human CA1 structure and memory impairment in PD patients. Further studies are required to uncover the downstream sequelae of alpha-synuclein aggregation in the hippocampus.

4.3. Clinical and methodologic considerations {#s0085}
---------------------------------------------

Approximately 80% of PD patients with \>10 years disease duration develop dementia ([@bb0060]; [@bb0125]), and the neuropathology underlying dementia in PD is heterogeneous. Specifically, AD-related amyloid plaques and tau tangles frequently co-exists with Lewy-body pathology in PDD patients at autopsy ([@bb0100]; [@bb0125]). With this in mind, we took several steps to limit the potential confound of dual PD/AD pathology in our study. First, we recruited a cohort where all but one of our PD participants had \<10 years disease duration, since younger patients at the earlier stages of disease are less likely to have dual pathology. Second, most of our PD participants (96.5%) were non-demented. Studies have shown that non-demented PD patients less commonly express concomitant AD pathology at autopsy and, when amyloid is present, it typically does not reach a severity to justify a pathological diagnosis of AD ([@bb0100]; [@bb0185]). A recent study using amyloid and tau PET imaging in non-demented PD patients, with and without cognitive impairments, found that none of the PD patients had tau PET binding in brain regions reflecting likely AD pathology. The authors concluded that cognitive deficits in non-demented PD do not appear to reflect measurable AD pathology ([@bb0255]). Third, we included CSF biomarkers in a subgroup of participants, including all 3 of the participants with dementia, the group the most likely to have dual PD/AD pathology. Therefore, we feel confident that the relationship between CA1-SP thickness and episodic memory in our PD cohort is not due to concomitant AD, but rather a primary feature of PD itself.

Another strength of our study was that we were able to show the correlation between 7T measures of CA1-SP and episodic memory was robust after including other critical clinical predictors of PD cognitive impairment. Indeed, older age and longer duration of motor symptoms, fewer years of education, and male gender, have all been shown to correlate with severity of memory impairments in large PD cohorts ([@bb0060]). In our correlation analysis, age had a significant relationship with episodic memory and one recent PD study at 3 T showed total hippocampus volume correlated with disease duration when controlling for age ([@bb0245]). In our case, age and duration were not significant in the fully-adjusted regression model and CA1-SP remained a significant predictor of delayed cued memory. Therefore, in mild to moderate PD patients the relationship between CA1-SP thickness and memory appears to be beyond the effects of disease duration and age.

On our 7T high-resolution images we based our thickness estimation procedures on manual tracing of curvilinear CA1-SP ROIs, which could be prone to inter-rater segmentation differences. However, we achieved good inter-rater reliability (ICC = 0.86), comparable to the typical intra-rater ICC range for hippocampal subfields (0.80--0.95).

4.4. Conclusions and future directions {#s0090}
--------------------------------------

Autopsy studies have recently established a relationship between CA1 Lewy-body pathology and episodic memory impairments in patients with Lewy Body Dementia ([@bb0010]); our study demonstrated a similar relationship in patients with PD, many of whom had only mild memory impairments. Further studies investigating whether hippocampal subfield changes are domain-specific or whether they develop before the onset of PD cognitive impairments are warranted. Indeed, the results from our analysis can empower future studies to validate and expand the relationships between hippocampal subfields and cognitive impairments in PD, and ultimately provide clarity to understanding the neuroanatomical underpinnings of this devastating symptom.

Appendix A. Supplementary data {#s0120}
==============================
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